The current study is population-based; patients were not selected on the basis of family history of prostate, breast, or ovarian cancer, which offers a less-biased assessment of the role of BRCA2 protein-truncating mutations in men from the general population. The gene discussed is BRCA2; the disease is ovarian carcinoma.